FDB (First Databank, Inc.)’s Post

Some fascinating insight about the potential role of neoantigens in a future where personalised cancer vaccines are ubiquitous. Given the manufacturing challenge, I'm interested to see what can be reapplied from Cellular Origins' scalable manufacture of cell and gene therapy.

Cancer cells exhibit distinctive cell-surface peptides called neoantigens, representing promising targets for cutting-edge cancer vaccines designed to activate the immune system against these malignant cells. The exploration of neoantigens for vaccine development is facilitated by advanced tools like custom peptide microarrays. RobustDx's custom assays prove to be invaluable, offering a high dynamic range and sensitivity. Our assays serve as a powerful resource for discovering and analyzing immunodominant antibody responses, providing crucial insights into treatment responses. These capabilities can not only expedite vaccine research and development, but also enhance our understanding of immune responses, ultimately contributing to more effective cancer treatments. #CancerResearch #VaccineDevelopment #Immunotherapy https://lnkd.in/dh6Ne4-f

This news today marks a huge development and a significant step forward in cancer treatment in England. 👭 🧑🤝🧑 Thousands of NHS cancer patients in England are expected to have access to trials of a revolutionary cancer treatment using vaccines. 🏥 Thirty hospitals have already enrolled in the Cancer Vaccine Launch Pad. This platform is designed to connect patients with upcoming clinical trials that use cutting-edge mRNA technology. 🔬 The mRNA technology utilised in these vaccines is similar to that used in the COVID-19 vaccines approved during the pandemic. 💉The vaccines aim to prime the immune system to recognise and eliminate any residual cancer cells. 🦠 ⁠By targeting remaining cancer cells, these vaccines can potentially reduce the risk of cancer returning. This initiative represents a promising advancement in personalised cancer therapy, leveraging the latest in mRNA vaccine technology to offer new hope for patients. It highlights the continued innovation in medical research and the potential for vaccines, which we normally associate with preventing disease, to play a significant role in cancer treatment. While there is great optimism about the potential for mRNA cancer treatment vaccines, it’s still early days. The vaccines remain in the experimental stage and are only available as part of clinical trials. More than 200 patients in the UK, Germany, Belgium, Spain and Sweden will be recruited to the clinical trial and will receive up to 15 doses of the personalised vaccine. The study is not due to be completed until 2027. Moderna and BioNTech SE have begun or are planning trials of mRNA vaccines against a range of tumour types including lung, breast and bladder cancer. https://bbc.in/4bYbcpl #CancerTreatment #England #NHS #ClinicalTrials #mRNA #Vaccines #CancerResearch #CancerPrevention #TargetedTreatment #VaccineTechnology #TeamKVA

Two articles in Nature highlight the potential for cancer vaccines - 'the new frontier in immunotherapy' and 'cancer vaccines - reasons for optimism'…. Oxford Vacmedix is developing vaccines to treat cancer using ground-breaking new technology that maximises the effect on the body's immune system to fight the cancer. The lead cancer vaccine, OVM-200, is in Phase 1 clinical trials and has already show excellent safety and a very strong immune response. The vaccine is being used to treat lung, prostate and ovarian cancer. The company invites offers of investment to continue the clinical development of OVM-200 https://lnkd.in/gihgBsRV https://lnkd.in/ezcxgyp4

Cancer vaccines are having a renaissance Moderna and Merck, along with BioNTech and Genentech, are advancing in the field of personalized cancer vaccines, focusing on various cancers including melanoma, lung, and pancreatic cancer. These vaccines are tailored to each individual's tumor by identifying specific mutations and creating a vaccine that trains the immune system to recognize and fight the cancer cells. The use of mRNA technology, which gained prominence during the COVID-19 pandemic, is central to this approach. Recent clinical trials have shown promising results, such as a significant reduction in the risk of cancer recurrence when combined with other treatments. This new generation of cancer vaccines aims to harness the body's immune system more effectively than previous therapies, offering hope for more durable cancer treatments across various types of the disease. https://lnkd.in/eNv7bJKY

We've been here before, the search for and research into cancer vaccines has been illusive and ongoing for 50+ years. 'Gamechangers' are frequently reported across pharma...but, Covid really did change the game in vaccines. Accelerating vaccines production, especially mRNA vaccines. " mRNA vaccines are one of the most exciting research developments to come out of the pandemic, and there are strong hints that they could become powerful treatment options for cancer."  Dr Iain Foulkes, Executive Director of Research and Innovation at Cancer Research UK (CRUK) Research UK This trial, using BioNTech IMFS technology has been able to custom-build personalized anti-cancer vaccines for trial patients in a matter of weeks. So maybe... #cancer #ASCO #NHS #vaccines

5 Cancer Vaccines to Watch in 2024 via BioSpace: https://bit.ly/47zMMjq. "Several cancer vaccine candidates are flying through clinical trials with promising results. Unlike traditional vaccines that aim to prevent a disease from occurring, therapeutic cancer vaccines train the patient’s immune system, enabling T cells to patrol the body for cancer cells and destroy them. Progress in personalized medicine has made it easier and much more affordable to sequence patient genomes, pull out unique cancer signatures and make vaccines encoding these neoantigens. BioSpace compiled a list of five cancer vaccines in mid- to late-stage development and sought insights from two experienced researchers on their respective merits." #CancerVaccines #AMMG #AgeManagementMedicine #CMEEducation #ContinuingMedicalEducation #CMEConferences

At last a positive outcome from the pandemic! A friend of mine in Germany had been talking to me for a number of years about a new treatment to help beat cancer. mRNA treatments can be tailored to the specific genetic profile of an individual’s tumour, enhancing the precision and efficacy of the therapy. These treatments for cancer represent a promising frontier in oncology due to several distinct advantages: 1. Personalized Medicine 2. Rapid Development 3. Stimulation of Immune Response 4. Safety Profile 5. Versatility 6. Combination Therapies 7. Minimal Side Effects 8. Scalability These benefits underscore the potential of mRNA treatments to revolutionise cancer therapy by offering more effective, personalised, and safer treatment options. #cancer #vaccine #breakthrough Thousands of cancer patients to trial personalised vaccines.